Piper Sandler Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $90.00

TransMedics Group (NASDAQ:TMDX) had its target price cut by Piper Sandler from $110.00 to $90.00 in a research report report published on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms also recently commented on TMDX. TD Cowen dropped their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Tuesday, December 3rd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird cut their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.80.

TransMedics Group Trading Down 2.2 %

TransMedics Group stock opened at $64.26 on Wednesday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a 50-day moving average price of $97.26 and a two-hundred day moving average price of $131.98. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 68.36 and a beta of 2.06. TransMedics Group has a 52-week low of $63.42 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) earnings per share. Sell-side analysts expect that TransMedics Group will post 1 earnings per share for the current year.

Insider Activity

In related news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,042 shares of company stock worth $3,563,985. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in TMDX. International Assets Investment Management LLC bought a new position in shares of TransMedics Group in the 2nd quarter valued at about $47,000. USA Financial Formulas bought a new position in shares of TransMedics Group in the 3rd quarter valued at about $55,000. Quarry LP boosted its stake in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI boosted its stake in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.